Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective study to evaluate the Clinical Outcomes of Biosimilar Follitropin Alfa (Bemfola ®) comapared to the established recombinant FSH preparations [Follitropin Alfa (Gonal-f) or Follitropin Beta (Puregon)] for Controlled Ovarian Stimulation

Trial Profile

A Retrospective study to evaluate the Clinical Outcomes of Biosimilar Follitropin Alfa (Bemfola ®) comapared to the established recombinant FSH preparations [Follitropin Alfa (Gonal-f) or Follitropin Beta (Puregon)] for Controlled Ovarian Stimulation

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Follitropin alfa (Primary) ; Follitropin beta
  • Indications Female infertility
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2018 New trial record
    • 10 Oct 2018 Results presented at the American Society for Reproductive Medicine Scientific Congress 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top